Company / Interest Expense per Share
ALNYLAM PHARMACEUTICALS, INC. Interest Expense per Share History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense per Share
$0.98
FY2023
5-year range
$0.00 / $0.98
FY2020-FY2023
Trend
+39.1%
vs FY2022
Sector context
#8 of 43
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s interest expense per share of $0.98 is higher than 81% of companies in the Health Care sector (FY2023). Increased from $0.00 to $0.98 over the past 2 years.
Based on SEC 10-K filings.
0.98 in FY2023. Top quartile in the Health Care sector.
Increased from $0.00 to $0.98 over the past 2 years.
Health Care sector context is included.
Interest Expense per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 43This company $0.98 Sector average $9.80
▼
-90.0% below sector average
Key checks
Key Insights
- In FY2023, interest expense per share increased 39.1% year-over-year.
- Ranks #8 out of 43 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest Expense per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.98 | +39.1% |
| FY2022 | $0.70 | - |
| FY2021 | $0.00 | - |
| FY2020 | $0.00 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026